[B-type natriuretic peptide].
BACKGROUND
B-type natriuretic peptide is a neurohormone synthesized in the cardiac ventricles upon ventricular pressure overload and ventricular dilatation. This peptide with many favourable physiological properties has emerged as important candidate for development of diagnosis and prognostic tools and therapeutic agents in cardiovascular disease.


METHODS
Literature published until now shows the interest to measure B-type natriuretic peptide in the diagnosis of ventricular dysfunction or congestive heart failure. B-type natriuretic peptide is also a prognostic marker in patients with congestive heart failure and acute coronary syndrome. It could even help to guide patient treatment management. It is easily and rapidly measured at a reasonable cost. In general, a level less than 50 ng/l has a strong negative predictive value for congestive heart failure.


CONCLUSIONS
B-type natriuretic peptide is available in daily clinical practice. Future interest has focused on development of drugs that modulate its effects in treatment of decompensated congestive heart failure. Studies are in progress and first results seem to be promising.
Granel
B
B
Service de médecine interne, hôpital de La Timone, 264, rue Saint-Pierre, 13385 Marseille cedex 05, France. granel.brigitte@wanadoo.fr
D015415:Biomarkers / Q000032:analysis; D002318:Cardiovascular Diseases / Q000175:diagnosis / Q000188:drug therapy; D006333:Heart Failure / Q000175:diagnosis* / Q000473:pathology; D006801:Humans; D045283:Natriuretic Agents / Q000627:therapeutic use*; D020097:Natriuretic Peptide, Brain / Q000627:therapeutic use*; D011379:Prognosis; D012016:Reference Values
D015415:Biomarkers; D045283:Natriuretic Agents; D020097:Natriuretic Peptide, Brain